Since the inception of the Mayo Alzheimer's Disease Research Center in Rochester, MN and Jacksonville, FL in the early 1990's, the Education and Information Transfer Core (EITC) has been active in Rochester, Jacksonville, Minnesota, Florida and throughout the United States. In the EITC, as in the center at large, the administrative structure reflects full integration of the two sites. The ADRC Rochester has focused on underserved rural populations while the ADRC-Jacksonville has emphasized underserved African American populations. Through the EITC, the Mayo Clinic ADRC continues to provide education and information transfer activities at international, national, regional, local, and institutional levels. These activities have included traditional research presentations at scientific meetings, but more importantly have included a multi- media approach to training and education of professionals, paraprofessionals, and caregivers. In the past grant cycle, we meet over 85% of our ambitious aims. The number of recipients of EITC services has remained quite large At least 100 programs or presentations have been provided each year. Over 25,000 education units have been provided to professionals, paraprofessional or family members during the last 4 years. In the addition we have made progress on new initiatives not envisioned when the last renewal was submitted. . This is particularly true in the area of supporting the clinical core's efforts at recruitment and retention. The Mayo EITC works synergistically with the Alzheimer's Association and collaboratively with other ADRCs to further education and information transfer. We have and will continue to promote minority scientist development within our broader efforts continue to cultivate our professional education and training programs. To this end, we have partnered closely with the new Mayo Clinical and Translational Science (CTSA) Award. Our on-going assessment and program evaluation have focused our planned efforts for the next five-years. The EITC will maintain its past strengths, address all requirements of the RFP, and support the Center at large in it's focus on Mild Cognitive Impairment and non-AD dementias.

Public Health Relevance

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016574-12
Application #
8065952
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
12
Fiscal Year
2010
Total Cost
$186,288
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Wilmoth, Kristin; LoBue, Christian; Clem, Matthew A et al. (2018) Consistency of traumatic brain injury reporting in older adults with and without cognitive impairment. Clin Neuropsychol 32:524-529
Jones, David T; Knopman, David S; Graff-Radford, Jonathan et al. (2018) In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology 90:e947-e954
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Wennberg, Alexandra M V; Lesnick, Timothy G; Schwarz, Christopher G et al. (2018) Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci 73:1244-1250
Wennberg, Alexandra M V; Hagen, Clinton E; Edwards, Kelly et al. (2018) Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. Int J Geriatr Psychiatry 33:1114-1120
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Sahoo, Aradhana; Bejanin, Alexandre; Murray, Melissa E et al. (2018) TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia. J Alzheimers Dis 64:1227-1233

Showing the most recent 10 out of 1014 publications